BAUSCH HEALTH COS INC
BHCNYSETrading Snapshot
- Day Range
- $171.24 β $174.15
- 52-Week Range
- $4.33 β $8.00
- Volume
- $2.80B
- Avg Volume
- $2.10B
- Shares Outstanding
- 374.0M
- Next Earnings
- Nov 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $10.27B
- Last Q Revenue
- $2.85B
- P/E Ratio
- -1.9
- P/S Ratio
- 0.2x
- EPS (TTM)
- $-2.93
- Dividend Yield
- 0.00%
- Dilution (1yr)
- β0.4%
Why Investors Own BHC
- βHigh-growth profile β revenue up +2.4% YoY with expanding US Equity exposure.
- βHealthy economics β 70% gross margin and 17% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BAUSCH HEALTH COS INC
BHCAbout BAUSCH HEALTH COS INC
Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
BAUSCH HEALTH COS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift BHC price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
BAUSCH HEALTH COS INC announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.